Protagenic Therapeutics, Inc.
149 Fifth Avenue
New York, NY 10010
December 30, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Re: | Protagenic Therapeutics, Inc. Registration Statement on Form S-3 Filed June 14, 2024 File No. 333-280244 |
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence with EDGAR on December 20, 2024, in which we, Protagenic Therapeutics, Inc., requested to accelerate the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-280244) (the “Registration Statement”) so that it would become effective on December 24, 2024 at 12:00 pm, Eastern Standard Time, or as soon as practicable thereafter. The Company is no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the effective date.
| Very truly yours, | ||
| PROTAGENIC THERAPEUTICS, INC. | ||
| By: | /s/ Alexander K. Arrow | |
Alexander K. Arrow Chief Financial Officer | ||
cc: Dean Colucci, Duane Morris LLP